At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
Naltrexone SR 32 mg/bupropion SR 360 mg/day +2 moredrug
Likely dose
Naltrexone SR 32 mg/bupropion SR 360 mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Naltrexone Sustained Release (SR) 32 mg and Bupropion Sustained Release (SR) 360 mg Combination Therapy in Functional Magnetic Resonance Imaging (fMRI) Changes in Overweight or Obese Subjects
In Brief
A Phase 2 clinical trial evaluating Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, and 1 other intervention for Obesity. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The purpose of this study was to assess the effect of naltrexone SR/bupropion SR (NB) on brain function in response to food cues using functional magnetic resonance imaging in overweight or obese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartSep 2008
Primary CompletionJun 2010
TodayJul 2026
First PostedJul 9, 2008
Enrollment StartSep 1, 2008
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.0 years ago
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/daydrug
Placebodrug
fMRI scanother
fMRI to assess the effects of the drug/placebo on areas of the brain